Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» bimekizumab
bimekizumab
UCB Wins FDA Approval for Plaque Psoriasis Therapy After Regulatory Setbacks
BioSpace
Thu, 10/19/23 - 10:15 am
UCB
bimekizumab
psoriasis
FDA
Bimzelx
UCB's bimekizumab finally back on the FDA's review list after May rejection
Fierce Pharma
Wed, 12/28/22 - 08:40 pm
UCB Pharma
psoriasis
bimekizumab
FDA
UCB’s FDA setback delays competition in U.S. with blockbuster J&J psoriasis drug
MedCity News
Sun, 05/15/22 - 11:12 pm
UCB Pharma
bimekizumab
psoriasis
FDA
JNJ
From Pfizer to Argenx: A look at potential blockbusters awaiting FDA decisions this year
Fierce Pharma
Mon, 09/13/21 - 11:38 pm
FDA
Pfizer
Argenx
UCB Pharma
Roche
efgartigimod
bimekizumab
faricimab
abrocitinib
Clarivate Drugs to Watch Report Highlights Four Likely Blockbusters Among Drugs Launching in 2021
PR Newswire
Tue, 03/9/21 - 10:45 am
Clarivate
Biogen
Eisai
aducanumab
UCB Pharma
bimekizumab
Relugolix
Pfizer
Takeda
Myovant
vericiguat
Bayer
Merck
Aducanumab tops 2021’s biggest potential launches
EP Vantage
Mon, 01/18/21 - 01:04 pm
drug launches
Biogen
Eisai
aducanumab
efgartigimod
Argenx
Evrenzo
FibroGen
Astellas
AstraZeneca
Leqvio
Novartis
UCB Pharma
bimekizumab
Ascendis Pharma
Bluebird Bio
Bristol-Myers Squibb
ide-cel
liso-cel
AXS-05
Axsome Therapeutics
voclosporin
Aurinia
UCB touts another psoriasis win, this time over Cosentyx, as they look to break into packed market
Endpoints
Fri, 07/24/20 - 11:17 am
UCB Pharma
psoriasis
bimekizumab
Cosentyx
UCB’s growth driver squares up against the competition
EP Vantage
Thu, 06/11/20 - 12:20 pm
UCB Pharma
bimekizumab
psoriasis
clinical trials
Novartis
Cosentyx
UCB posts more supportive data from Humira rival bimekizumab
Pharmaforum
Fri, 12/6/19 - 09:31 pm
UCB Pharma
bimekizumab
AbbVie
Humira
psoriasis
biosimilars
UCB adds on more positive PhIII data for IL-17A/17F inhibitor bimekizumab, clearing a path to the FDA
Endpoints
Fri, 11/15/19 - 11:12 am
UCB Pharma
bimekizumab
psoriasis
clinical trials
UCB's bispecific beats J&J's Stelara in psoriasis phase 3
Fierce Biotech
Fri, 10/18/19 - 07:47 pm
UCB Pharma
bispecific antibodies
bimekizumab
JNJ
Stelara
psoriasis
UCB tries to win some respect in the crowded psoriasis market with a dual IL-17 approach — and it won't be easy
Endpoints
Thu, 10/17/19 - 10:24 am
UCB Pharma
Amgen
psoriasis
bimekizumab